chartmojo

SRPT regression play

שורט
chartmojo מעודכן   
NASDAQ:SRPT   Sarepta Therapeutics, Inc.
3
100% pop should regress some
הערה:
important Duchens Muscular Dystrophy reversal/approval..small market however
הערה:
Frankly after researching this companies drug and Duchenne Muscular Dystrophy i find myself rooting for this company. This stock popped some 95% on an approval of their drug that delays the onset of the debilitating effects of this little known genetic disease in children. While there was and may be more regression opportunities in the price from a technical perspective, especially for a scalper like me, I'm hoping the company's stock actually ultimately goes to the moon and that those dedicated individuals involved in this company prosper because they deserve it.

כתב ויתור

המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.